HeartSciences Inc. reported fiscal 2026 revenue of $4.3K, essentially flat with fiscal 2025, and a net loss that widened modestly to $9.142M from $8.765M a year earlier; diluted loss per share was $(3.48) for FY 2026 versus $(9.34) in FY 2025.Financial HighlightsBusiness HighlightsOriginal SEC Fili…
HeartSciences amended CFO Danielle Watson's employment agreement and granted her 25,000 RSUs, including severance and accelerated vesting protections tied to the proposed Fortitude merger.Original SEC Filing: HeartSciences Inc. [ HSCS ] - 8-K - Jul. 10, 2026This is an AI-powered summary. It may con…
HeartSciences will appoint Andrea Childs as Chief Executive Officer and Erik Ellingson as Chief Financial Officer, effective at the Closing of a pending merger that increases the board from five to nine members.Original SEC Filing: HeartSciences Inc. [ HSCS ] - 8-K - Jun. 26, 2026This is an AI-powe…
